Future Opportunities in Genitourinary Cancers
Siamak Daneshmand, MD, provides closing remarks on the management of genitourinary cancers and the future of care.
Source: ajmc.com
Genomic Landscape News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Genomic Landscape. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Genomic Landscape Today - Breaking & Trending Today
Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT
First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...
Source: marketscreener.com
World of Genomics: Malaysia
This week's World of Genomics takes us on a trip to Malaysia. A haven for ecologists, what does Malaysia's genomics field have to offer?
Source: frontlinegenomics.com
Genomenon Partners with Don't Forget Morgan to Provide New Hope for Rare Disease
Ann Arbor, Michigan (PRWEB) February 22, 2022 -- Genomenon, Inc. recently announced a partnership with Don’t Forget Morgan, a nonprofit support organization
Source: prweb.com
Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors
Share this article Share this article SUZHOU, China, and ROCKVILLE, Md., June 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Investigational New Drug (IND) application for the company's novel Bcl-2 inhibitor, lisaftoclax (APG-2575), has been cleared by the US Food and Drug Administration (FDA) and the company is poised to initiate a clinical study of lisaftoclax as a single agent or in combination with ...
Source: prnewswire.com